Drug Profile
Abrezekimab - UCB/Vectura
Alternative Names: Immunomodulatory biologic - respiratory disease - UCB/Vectura; UCB 4144; VR-942Latest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator UCB; Vectura
- Class Antiasthmatics; Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Asthma